Ibrutinib plus Venetoclax in the Phase 3 Sympatico Study: what do the censoring rules tell us about the combination therapy?

Progression free survival is a frequently used primary endpoint of randomized clinical trials in cancer. Kaplan Meier method is broadly used to analyze progression free survival data. In Kaplan Meier method only patients with the event of interest contribute to the analysis. Patients that do not contribute to dataset are usually censored. Kaplan-Meier method is based on the assumption that the censored patients are not different than those who contribute to the dataset. Breaking this central assumption can lead to major imbalance in survival analysis.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Current Perspective Source Type: research